P/B
4,5
Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
$2.7B
Market Cap • 10/2/2026
2013
(13 years)
Founded
2017
(9 years ago)
IPO
NASDAQ
Listing Exchange
China
Country
Valuation
P/S
6,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,4
EPS
—
Market Cap
Market Cap
2,7B
EV
2,4B
EV/Revenue
5,3
EV/EBITDA
-9,5
EV/EBIT
-9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
-2,7B
Profitability
Gross Margin
56,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
52,7%
Capex/Revenue
1,4%
Capex/D&A
38,8%
Capex/OCF
-4,6%
SBC/OCF
—
% PPE
5,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
39%
CAGR Op. Income 5Y
-14,2%
CAGR Net Income 5Y
-18,9%
CAGR EPS 5Y
-25,5%
CAGR OCF 5Y
-18%
Leverage
N.D./EBITDA
1,5
Debt/Equity
0%
Current Ratio
2,1
Quick Ratio
1,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!